640 related articles for article (PubMed ID: 25169962)
1. Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab.
Bodini G; Savarino V; Peyrin-Biroulet L; de Cassan C; Dulbecco P; Baldissarro I; Fazio V; Giambruno E; Savarino E
Dig Liver Dis; 2014 Nov; 46(11):1043-6. PubMed ID: 25169962
[TBL] [Abstract][Full Text] [Related]
2. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study.
Papamichael K; Archavlis E; Lariou C; Mantzaris GJ
J Crohns Colitis; 2012 Oct; 6(9):924-31. PubMed ID: 22424843
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial.
Savarino E; Bodini G; Dulbecco P; Assandri L; Bruzzone L; Mazza F; Frigo AC; Fazio V; Marabotto E; Savarino V
Am J Gastroenterol; 2013 Nov; 108(11):1731-42. PubMed ID: 24019080
[TBL] [Abstract][Full Text] [Related]
5. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease.
Karmiris K; Paintaud G; Noman M; Magdelaine-Beuzelin C; Ferrante M; Degenne D; Claes K; Coopman T; Van Schuerbeek N; Van Assche G; Vermeire S; Rutgeerts P
Gastroenterology; 2009 Nov; 137(5):1628-40. PubMed ID: 19664627
[TBL] [Abstract][Full Text] [Related]
6. Crohn's disease management after intestinal resection: a randomised trial.
De Cruz P; Kamm MA; Hamilton AL; Ritchie KJ; Krejany EO; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Gibson PR; Sparrow M; Leong RW; Florin TH; Gearry RB; Radford-Smith G; Macrae FA; Debinski H; Selby W; Kronborg I; Johnston MJ; Woods R; Elliott PR; Bell SJ; Brown SJ; Connell WR; Desmond PV
Lancet; 2015 Apr; 385(9976):1406-17. PubMed ID: 25542620
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease.
Bodini G; Giannini EG; Savarino V; Del Nero L; Pellegatta G; De Maria C; Baldissarro I; Savarino E
Scand J Gastroenterol; 2016 Sep; 51(9):1081-6. PubMed ID: 27207330
[TBL] [Abstract][Full Text] [Related]
8. Prevention of postoperative recurrence of Crohn's disease by Adalimumab: a case series.
Savarino E; Dulbecco P; Bodini G; Assandri L; Savarino V
Eur J Gastroenterol Hepatol; 2012 Apr; 24(4):468-70. PubMed ID: 22266834
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study.
Tonelli F; Giudici F; Asteria CR
Dis Colon Rectum; 2012 Aug; 55(8):870-5. PubMed ID: 22810472
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease.
Bodini G; Giannini EG; Furnari M; Marabotto E; Baldissarro I; Del Nero L; Assandri L; Moscatelli A; Savarino V; Savarino E
J Gastrointestin Liver Dis; 2015 Dec; 24(4):451-6. PubMed ID: 26697571
[TBL] [Abstract][Full Text] [Related]
11. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P
Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients.
Aguas M; Bastida G; Cerrillo E; Beltrán B; Iborra M; Sánchez-Montes C; Muñoz F; Barrio J; Riestra S; Nos P
World J Gastroenterol; 2012 Aug; 18(32):4391-8. PubMed ID: 22969204
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
Sandborn WJ; Hanauer SB; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh DG; Panaccione R; Wolf D; Kent JD; Bittle B; Li J; Pollack PF
Gut; 2007 Sep; 56(9):1232-9. PubMed ID: 17299059
[TBL] [Abstract][Full Text] [Related]
14. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.
Roblin X; Marotte H; Rinaudo M; Del Tedesco E; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
Clin Gastroenterol Hepatol; 2014 Jan; 12(1):80-84.e2. PubMed ID: 23891927
[TBL] [Abstract][Full Text] [Related]
15. Postoperative therapy with infliximab prevents long-term Crohn's disease recurrence.
Regueiro M; Kip KE; Baidoo L; Swoger JM; Schraut W
Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1494-502.e1. PubMed ID: 24440221
[TBL] [Abstract][Full Text] [Related]
16. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
af Björkesten CG; Nieminen U; Sipponen T; Turunen U; Arkkila P; Färkkilä M
Scand J Gastroenterol; 2013 May; 48(5):543-51. PubMed ID: 23477356
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).
Dewint P; Hansen BE; Verhey E; Oldenburg B; Hommes DW; Pierik M; Ponsioen CI; van Dullemen HM; Russel M; van Bodegraven AA; van der Woude CJ
Gut; 2014 Feb; 63(2):292-9. PubMed ID: 23525574
[TBL] [Abstract][Full Text] [Related]
18. Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn's Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab.
Sorrentino D; Marino M; Dassopoulos T; Zarifi D; Del Bianco T
PLoS One; 2015; 10(12):e0144900. PubMed ID: 26670274
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effectiveness of infliximab and adalimumab in preventing postoperative recurrence in patients with Crohn's disease: an open-label, pilot study.
Tursi A; Elisei W; Picchio M; Zampaletta C; Pelecca G; Faggiani R; Brandimarte G
Tech Coloproctol; 2014 Nov; 18(11):1041-6. PubMed ID: 24915941
[TBL] [Abstract][Full Text] [Related]
20. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study.
Feagan BG; Panaccione R; Sandborn WJ; D'Haens GR; Schreiber S; Rutgeerts PJ; Loftus EV; Lomax KG; Yu AP; Wu EQ; Chao J; Mulani P
Gastroenterology; 2008 Nov; 135(5):1493-9. PubMed ID: 18848553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
